Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-12-25
pubmed:abstractText
The ability to measure the opsonic activity of antibody may be critical in choosing among potential therapeutic candidates. It has been shown in numerous studies that the ability of antibody to mediate clearance of bacterial organisms in animal models and in humans is related to its in vitro opsonic activity and not solely to its antigen binding activity. We have developed a rapid and robot adaptable opsonophagocytosis assay for Staphylococci based on bioluminescence produced by bacteria transfected with the luciferase operon. Opsonophagocytosis is measured by the loss of bioluminescence as bacteria are opsonized by phagocytes and killed. Pagibaximab is a humanized monoclonal anti-lipoteichoic acid (LTA) antibody opsonic for S. epidermidis and S. aureus, which we used to develop this rapid bioluminescence assay.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1557-8348
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
487-91
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
A rapid opsonic assay for measuring killing of bioluminescent Staphylococcus epidermidis.
pubmed:affiliation
AFG Biosolutions, Gaithersburg, Maryland. marty.burkhardt@afgbio.com
pubmed:publicationType
Journal Article